Study of Daxdilimab (HZN-7734) in Participants With Active Proliferative Lupus Nephritis
Status:
Not yet recruiting
Trial end date:
2026-12-09
Target enrollment:
Participant gender:
Summary
Phase 2, multicenter, double-blind, randomized, placebo-controlled, parallel-group trial to
evaluate the efficacy and safety of daxdilimab in patients with active, proliferative lupus
nephritis (LN).